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ABSTRACT
Pit-1, a member of the POU-homeo domain protein family, is one
of the transcription factors responsible for anterior pituitary devel-
opment and pituitary-specific gene expression. Here, we describe
seven children with GH, PRL, and TSH deficiency from three, re-
portedly unrelated, Middle Eastern families, harboring a newly rec-
ognized Pro-.Ser recessive mutation in codon 239 of the Pit-1 gene.
The mutated residue is located at the beginning of the second a-helix
of the POU-homeodomain and is strictly conserved among all POU
proteins. The Pro239Ser mutant binds DNA normally but is unable
to stimulate transcription. (J Clin Endocrinol Metab 83: 2079–2083,
1998)
Pit-1/GHF-1 is a pituitary-specific transcription factor re-quired for pituitary development and for expression of
several anterior pituitary hormones (1–3). Pit-1 transactivates
expression of the genes coding for GH, PRL, and TSH-b
(4–8), among others. In addition to its role in cell-specific
expression, Pit-1 also plays an essential role in the develop-
ment of somatotroph, lactotroph, and thyrotroph cells in the
anterior pituitary. As a member of the POU family, Pit-1
contains a highly conserved bipartite DNA-binding domain
consisting of the POU-homeodomain (60 amino acids), re-
quired for low-affinity DNA binding, and of the POU-spe-
cific domain (approximately 75 amino acids) responsible for
the specificity of DNA binding and for possible interactions
with other proteins (9). The major transactivating function of
Pit-1 resides in the N-terminal region of the protein, which
functions as an independent activation domain when con-
nected to a heterologous DNA-binding domain (1, 10).
Abnormalities in the Pit-1 gene were first observed in Snell
and Jackson dwarf mice. Their consequence was a combined
pituitary hormone deficiency (CPHD) with hypoplasia of the
anterior pituitary and no production of GH, PRL, or TSH (11).
A number of CPHD patients are known to have a point
mutation in the Pit-1 coding sequence (12–20). Some of these
mutations affect the DNA-binding capacity (12, 20) of the
Pit-1 protein, others alter its transactivation properties (13–
15). From a comparison of their pedigrees, it seems that
some mutations in the Pit-1 gene (Arg271Trp and Pro24Leu)
lead to a dominant-negative phenotype (13, 15–19); others
(Arg172stop, Glu250Stop, Ala158Pro, Arg143Gln), to a re-
cessive phenotype (14, 15, 20).
Here, we report the identification of a novel homozygous
Pro239Ser mutation in the Pit-1 gene of seven Middle Eastern
hypopituitary children from three reportedly unrelated fam-
ilies. In addition, we present the properties of the mutant
Pit-1 protein, with respect to transactivation, DNA binding,
and interaction with its wild-type counterpart.
Materials and Methods
DNA extraction, PCR amplification, and automated
direct sequencing
For DNA extraction from blood spots (5 mm2) on filter paper, we used
the ChelexR 100 chelating resin, as described by Walsh and co-workers
(21). PCR was used to amplify the six Pit-1 exons independently, using
six pairs of oligonucleotides corresponding to the intron/exon bound-
aries (15). Reactions were carried out as follows: approximately 100 ng
genomic DNA, 20 pmol of each primer, 200 mmol/L of each nucleotide,
1 U Dynazyme polymerase, and 13 Dynazyme reaction buffer were
mixed in a final vol of 100 mL. Reactions were cycled 30 times for 1 min
at 94 C, 1 min at 55 C, and 1 min at 72 C. The amplified products were
electrophoresed on 1.5% agarose gel and stained with ethidium bromide
to evaluate their size, purity, and quantity. Sequencing was performed
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directly on the amplified fragments, thus allowing immediate evaluation
of heterozygosity.
Site-directed mutagenesis
We used the CHAMELEON double-stranded, site-directed mutagen-
esis kit from Stratagene Cloning Systems (La Jolla, CA) to obtain the
mutated Pit-1 complementary DNA (cDNA). A plasmid, containing
nonmutated human Pit-1 cDNA cloned behind the RSV promoter
(pRSVhPit-1) (22), was used as a template.
The oligonucleotide 59CTCTTGAGAAGAAGATTTATTCTGTTC-
TCC39, containing the specific T-to-C substitution in codon 239, on the
antisense strand, was employed. Mutated clones were tested by DNA
sequencing and restriction analysis.
In vitro transcription/translation reactions
For in vitro transcription and translation, both the wild-type and the
mutant Pit-1 cDNA were inserted into the XbaI-XbaI sites of plasmid
pSVK3 from Pharmacia LKB Biotechnology (Uppsala, Sweden), which
contains a T7 promoter. The in vitro reactions were carried out using the
coupled transcription/translation system: TnTa Coupled Reticulocyte
Lysate Systems (from Promega, Madison, WI) and [35S]-labeled methi-
onine. Translation products were checked by electrophoresis on 5%
polyacrylamide gels, and two major species (31 and 33 kDa) were ob-
served, as expected (data not shown).
Gel-retardation assays
For the binding assays, we used the same amount of in vitro translated
proteins, as judged by protein gel autoradiography (overnight expo-
sure). The assays were performed in a mixture containing 2 mL translated
protein solution, 1 mg poly dIdC, 7 mmol/L HEPES (pH 7.9), 4% glyc-
erol, 4% Ficoll, 100 mmol/L KCl, 1 mmol/L MgCl2, 0.1 mmol/L EDTA,
2 mmol/L dithiothreitol, and 10,000 cpm labeled hPRLP1 oligonucleo-
tide (8), in a final vol of 20 mL. Two microliters of anti-Pit-1 antibodies
or control serum was added when necessary. Binding was carried out
for 30 min at 4 C (1 h with antibodies), after which samples were loaded
on a 5% polyacrylamide gel, in TBE 0.5X, for electrophoresis.
Production of anti-Pit-1 antibodies
A fragment of human Pit-1 cDNA, containing the coding regions for
the N-terminus and a small part of the POU-domain (amino acids 1–193),
was cloned in the pT7 bacterial expression vector and expressed in the
bacterial strain BL21 after addition of 100 mmol/L IPTG and incubation
at 37 C for 1 h. The approximately 23-kDa protein was subsequently
purified for use as an antigen. The activity of the serum from injected
rabbits was tested on Western blots (data not shown) with pituitary-
derived cell extracts (GC, GH3), and the expected 31- to 33-kDa doublet
bands corresponding to Pit-1 were obtained. We observed no extra
bands corresponding to other POU family members, such as Oct-1,
proving the high specificity of the antibodies against Pit-1. As expected,
no bands appeared in the negative control performed with nonpituitary
cell (HeLa) extracts.
Cotransfection assays
Human HeLa cells were plated on 60-mm plates at a density of 5 3
105 cells per plate and transfected with 5 mg of reporter plasmid
p(GH1)6XTKCAT (23). The amount of effector plasmid was kept con-
stant by addition of RSV-bgal, where appropriate, as indicated in the
figure legends. We used the calcium phosphate copreciptation method
for transfection. Cells were harvested 48 h after transfection, and chlor-
amphenicol-acetyl-transferase (CAT) assays were performed as previ-
ously described (23). The data shown are averages of at least three
independent experiments, with error bars indicating the sem.
Oligonucleotides and enzymes
The oligonucleotides used in this study were from Eurogentec (Se-
raing, Belgium) and the enzymes from Boehringer, Eurogentec, Gibco-
BRL, New England Biolabs, and Pharmacia.
Results
Subjects and endocrine studies
All described patients presented a clinical picture of con-
genital hypothyroidism and early growth failure and were
referred to the King Faisal Specialist Hospital and Research
Center. Studies were carried out with the informed consent
of all parents.
The seven children were from three, reportedly indepen-
dent families from the Al-Baha region in the Southwest of
Saudi Arabia. In each case, the parents were second-degree
relatives (see Fig. 1) and of normal stature for this commu-
nity. The maternal height ranges from 149.5 to 159.2 cm and
the paternal height, from 162.6 to 166.4 cm.
All seven children were GH-, PRL-, and TSH-deficient. In
all cases, serum GH concentration was less than 0.3 mg/L,
after a clonidine stimulation test or insulin tolerance test;
basal PRL concentration in serum was ,3 mg/L in either
hypothyroid (n 5 2) or euthyroid (n 5 5) conditions, and
thyroid hormone levels were below the reference range for
the age, with undetectable serum concentrations of TSH
(,0.1 mIU/L). In each case, a so-called empty sella turcica
was visualized by computed tomography scan.
All children were treated with l-T4 from early infancy.
They also received a GH therapy, which started between the
ages of 4 months and 3 yr plus 4 months. The height deficit,
after adjustment for midparental height sd increased with
advancing age, amounting to 22.9 sd at early start and 26.0
sd at latest start of GH therapy.
Molecular studies
A new point mutation in the Pit-1 gene. The human Pit-1 gene
is 17-kb long and composed of six coding exons (24). For each
family member analyzed, all six exons of the Pit-1 gene were
amplified by PCR and directly sequenced. Sequence analysis
revealed only one alteration, a T-.C transversion in codon
239, located in exon 6. This alteration leads to the substitution
of serine for proline at codon 239. The affected children are
all homozygous, the unaffected parents all heterozygous for
this mutation.
Pro239Ser mutant is unable to transactivate. To analyze the
functional effects of the Pro239Ser mutation, we first used
site-directed mutagenesis to produce an identical substitu-
tion in human Pit-1 cDNA, borne by the expression vector
pRSVhPit-1. We shall refer to the parental plasmid as
pRSVPit-1WT and to the plasmid bearing the Pro239Ser mu-
tation as pRSVPit-1M. Cotransfection experiments in HeLa
cells were performed using one of the Pit-1 expression vec-
tors with a reporter plasmid, p(GH1)6XTKCAT, bearing six
FIG. 1. Pedigrees of the three families with CPHD. Squares, Males;
circles, females; solid symbols, individuals who are homozygous for
the mutation in the Pit-1 gene; half-solid symbols, persons who are
heterozygous at this location; dotted symbols, phenotypically normal
individuals who were not examined.
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copies of the first Pit-1 binding site of the human GH pro-
moter (hGH1: from 271 to 291, see Ref. 8), inserted upstream
from the TK promoter and the CAT reporter gene. As shown
in Fig. 2, the mutant Pit-1 was unable to increase transcrip-
tion of the (GH1)6XTKCAT fusion-gene construct, whereas
wild-type Pit-1 stimulates its transcription 5-fold.
The DNA binding properties of the Pit-1 mutant are unaltered.
35S-labeled wild-type and mutant Pit-1 proteins from in vitro
transcription/translation reactions were used to test the abil-
ity of the Pro239Ser mutant to bind DNA in gel retardation
assays. Both proteins are of the correct apparent molecular
size (33 or 31 kDa, depending on the methionine at which
translation is initiated) (data not shown). As shown in Fig. 3,
the mutated and wild-type Pit-1 proteins bind with the same
affinity to the first Pit-1 DNA-binding site of the human PRL
gene (hPRL1P: from 235 to 264, see Ref. 8). The complexes
are specific, because they disappear with an excess of cold
hPRL1P oligonucleotide but not with an excess of cold, non-
specific DR4 oligonucleotide. The specificity is further con-
firmed by the fact that the shifted bands disappear in the
presence of anti-Pit-1 antibodies but not in the presence of
control serum. A nonspecific lower band is observed with
unprogrammed reticulocyte lysate.
Coexpression of the Pro239Ser mutant interferes with the wild-
type Pit-1 activity. Because the unaffected parents are all het-
erozygous for the Pro239Ser mutation, we sought to test the
ability of the mutant form to interfere with transactivation of
reporter gene expression by wild-type Pit-1. To this end, we
cotransfected HeLa cells with the p(GH1)6XTKCAT reporter
plasmid and either 14 or 28 mg of expression vector, this
meaning either pRSVbgal alone (control) or equal amounts
of two plasmids: pRSVbgal and pRSVPit-1WT, pRSVbgal
and pRSVPit-1M, or pRSVPit-1WT and pRSVPit-1M. As
shown in Fig. 4, the CAT activity doubles when the amount
of pRSVPit-1WT is increased from 7 mg to 14 mg, whether or
FIG. 2. Transfection of HeLa cells with
vectors expressing either wild-type or
Pro239Ser mutant Pit-1. The calcium
phosphate precipitation technique was
used to transfect the cells. We used 5 mg
of reporter plasmid and 10 mg of expres-
sion vector per plate. CAT assays were
performed overnight with 25 mg total
cell extract per plate, prepared after a
48-h incubation.
FIG. 3. Binding of the wild-type and Pro239Ser mutant Pit-1 proteins
to the hPRL1 Pit-1 binding site. Both in vitro translated proteins were
tested in gel retardation assays with 32P-labeled hPRLP1 oligonu-
cleotide, corresponding to the first Pit-1 footprint sequence in the
proximal human PRL promoter (8).
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not pRSVPit-1M is also present. We also observe 2-fold lesser
transactivation by wild-type Pit-1 at both vector concentra-
tions when the mutated form is expressed. The Pro239Ser
form alone is unable to stimulate transcription of the reporter
plasmid.
Discussion
We have analyzed the Pit-1 sequence of three apparently
independent families in which hypopituitary children are
homozygous and phenotypically normal parents are het-
erozygous for a Pro239Ser mutation.
Proline 239 is strictly conserved among the Pit-1 proteins
of several species and among other related POU proteins
(Fig. 5), implying that it must play an important role in Pit-1
activity. This residue is located at the beginning of the second
a-helix of the homeodomain, which was originally described
as the Pit-1 DNA binding domain (3). In gel retardation
experiments, we show that the Pro239Ser mutant form of
Pit-1 is still able to recognize the first Pit-1 binding site of the
human PRL proximal promoter and specifically binds to this
sequence with about the same affinity as the wild-type Pit-1.
These results are in agreement with the three-dimensional
conformation of the POU domain [recently established for
Oct-1 (25) and for the Pit-1 POU domain (26) cocrystallized
with their respective binding sequence], which seems to in-
dicate that residue 239 is not in direct contact with DNA. In
addition, Proline 239 occupies the N-cap position of the helix
a2 in the Pit-1 homeodomain. Prolines are frequent at N-cap
positions of a-helices, where they play a stabilizing role (27).
In our mutant, proline 239 is replaced by a serine, another
residue known to have a stabilizing effect on a-helices when
in the N-cap position. Thus, one should not expect the sta-
bility of the second a-helix of the Pit-1 homeodomain, and
hence the conformation of the protein, to be seriously af-
fected by the Pro239Ser mutation. Furthermore, a genetic
screen used to define the important residues for Pit-1 DNA-
binding, based on loss of function of fusion proteins between
the transactivation domain of GCN4 and chemically mutated
Pit-1 DNA binding domains, failed to detect the Pro239Ser
mutation described here (28). All these considerations sup-
port our finding that this Pit-1 variant is capable of binding
DNA with the same affinity as the wild-type form.
The results of our cotransfection experiments (Fig. 2)
clearly show that the Pro239Ser mutation causes complete
loss of transactivation activity. The hypothesis of nonexpres-
sion of the mutated protein in HeLa cells must be rejected,
because activation by wild-type Pit-1 is partially inhibited
when the vector bearing the mutated cDNA is also present
(Fig. 4). Without expression of this cDNA, such an effect
would be hard to explain.
When pRSVPit-1WT and pRSVPit-1M are present in equal
amount (7 or 14 mg each) in cotransfected cells, the transac-
tivation potential of wild-type Pit-1 is reduced by 50% (Fig.
4). These in vitro results are in keeping with the clinically
observed recessive phenotype of this mutation if we assume
that a 50%-reduced level of Pit-1 activity is sufficient to
ensure a normal phenotype.
Because Pit-1 forms dimers on DNA through its POU-
specific domain, two mechanisms might account for the abil-
ity of the mutant to repress wild type Pit-1 activity: compe-
tition between mutated and wild-type Pit-1 for DNA binding
sites; or formation of inactive heterodimers. The first possi-
bility must be rejected because the reporter plasmid was in
excess in our experiments [as shown by the 2-fold increase
of CAT activity observed when the amount of vector ex-
pressing wild-type Pit-1 was doubled, whether this vector
was present alone or in combination with the vector express-
ing the mutated form (Fig. 4)]. We therefore suggest that the
observed inhibitory effect of the Pro239Ser protein is caused
by formation of heterodimers that can bind to DNA but
cannot stimulate transcription, as is the case with mutant
homodimers. This model suggests that the mutation of
FIG. 5. Alignment of POU protein homeodomains. The species to
which each Pit-1 belongs is indicated by an h (human), r (rat), or m
(mouse). Amino acids that are identical at any position are boxed. The
residue mutated in all patients is marked by an arrow. Regions that
form a-helices, according to the Oct-1 crystallographic structure (21),
are also shown by grey boxes.
FIG. 4. Transfection of HeLa cells with vectors expressing the wild-
type (pRSVPit-1WT) or mutant form of Pit-1 (pRSVPit-1M), intro-
duced alone or simultaneously. In all cases, 5 mg p(GH1)6XTKCAT
reporter plasmid was introduced, in addition to the expression vec-
tor(s). The total vector amount indicated on the horizontal axis (14 or
28 mg) refers to the total amount of pRSV-derived plasmid; when two
such plasmids were introduced simultaneously (hatched, grey, and
black boxes), each was present in half the indicated amount.
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Pro239 into a serine abolishes the interaction of Pit-1 with
another factor(s) required for transcriptional activation.
In brief, our data show that a single point mutation in
codon 239 of the Pit-1 gene, causing the substitution of a
serine for a proline, leads to the phenotype of GH, PRL, and
TSH deficiency and hypoplasia of the anterior pituitary,
when present in both Pit-1 alleles. Because heterozygous
individuals are seemingly unaffected, it further seems that a
50%-reduced level of Pit-1 activity is sufficient to ensure a
normal phenotype.
The newly recognized, natural, recessive Pit-1 mutation
that we describe has been found in only three Middle Eastern
families. The relatively frequent and apparently exclusive
occurrence of this mutation in a defined geographic region
is striking. This occurrence may be based on a so-called
founder effect, the three families having a single and com-
mon heterozygous ancestor in whom this mutation first
arose. Alternatively, we may be in the presence of a hot spot
for mutations in the Pit-1 gene within this ethnic community,
distinct from the Arg271Trp hot spot that has been described
in Caucasians and Mongolians (16).
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